Who are Cytokine-induced killer cell immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, RAK therapy, Cellular Matrix / A-CP-HA Kit, Mesenchymal Stem Cells (MSCs), IL-7/IL-15 pre-treated CD19 cells, Mesenchymal stromal cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cytokine-induced-killer-cell-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cytokine-induced killer cell immunotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cytokine-induced killer cell immunotherapy (Cytokine-induced killer cell immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy; adoptive T-cell immunotherapy. Area: Oncology.

phase 3 Cell therapy; adoptive T-cell immunotherapy Oncology Biologic Live · refreshed every 30 min

Target snapshot

Cytokine-induced killer cell immunotherapy (Cytokine-induced killer cell immunotherapy) — Sun Yat-sen University. Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes that recognize and kill tumor cells through multiple pathways including TCR and NK receptor engagement.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cytokine-induced killer cell immunotherapy TARGET	Cytokine-induced killer cell immunotherapy	Sun Yat-sen University	phase 3	Cell therapy; adoptive T-cell immunotherapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	Fundación Santiago Dexeus Font	marketed	Cell therapy / Regenerative medicine product
Mesenchymal Stem Cells (MSCs)	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
Mesenchymal stromal cells	Mesenchymal stromal cells	National Research Center for Hematology, Russia	marketed	Cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy; adoptive T-cell immunotherapy class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cytokine-induced killer cell immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/cytokine-induced-killer-cell-immunotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab